Placebo matching BI 690517

Phase 3

Placebo matching BI 690517 is one of 2 therapeutic programs targeting Kidney Disease, Chronic. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Kidney Disease, ChronicRecruiting

Kidney Disease, ChronicPhase 3

Recruiting

Competition

Competitive Landscape

3 competitors in Kidney Disease, Chronic

#DrugCompanyPhaseTrials

Jardiance

Boehringer Ingelheim

Phase 3

2 2

Placebo matching BI 690517

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 3Recruiting

Kidney Disease, Chronic

NCT06531824

Clinical

Trials by Indication[1]

Kidney Disease, Chronic1 trial

A Multicenter, International, Randomized, Double-blind, Placebo-controlled Clinical Trial of the Aldosterone Synthase Inhibitor BI 690517 in Combination With Empagliflozin in Patients With Chronic Kidney Disease

Recruiting· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT06531824·11,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo matching BI 690517. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo matching BI 690517. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: Boehringer Ingelheim

Placebo matching BI 690517

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2028

Trials by Indication[1]

Kidney Disease, Chronic1 trial

References

Drug Info

Quick Facts

Related News